Difference between revisions of "FEZF1-AS1"
Qianpeng Li (talk | contribs) |
|||
| Line 1: | Line 1: | ||
==Annotated Information== | ==Annotated Information== | ||
===Name=== | ===Name=== | ||
| − | FEZF1-AS1:FEZF1 antisense RNA 1<ref name="ref1" /> | + | Approved symbol: FEZF1-AS1:FEZF1 antisense RNA 1<ref name="ref1" /> |
| + | |||
| + | HGNC ID: HGNC:41001 | ||
| + | |||
| + | Ensembl ID: ENSG00000230316 | ||
| + | |||
| + | RefSeq ID: NR_036484 | ||
| + | |||
| + | LncBook transcript ID: HSALNT0288975 | ||
===Characteristics=== | ===Characteristics=== | ||
| Line 9: | Line 17: | ||
[[File:FEZF1-AS1-1.JPG|right|thumb|400px|'''''FEZF1-AS1''''' regulates GC cell proliferation<ref name="ref2" />.]] | [[File:FEZF1-AS1-1.JPG|right|thumb|400px|'''''FEZF1-AS1''''' regulates GC cell proliferation<ref name="ref2" />.]] | ||
| − | Dysregulation of FEZF1-AS1 participates in colorectal tumorigenesis and progression, which might be achieved, at least in part, through FEZF1 induction <ref name="ref1" />. | + | *Dysregulation of FEZF1-AS1 participates in colorectal tumorigenesis and progression, which might be achieved, at least in part, through FEZF1 induction <ref name="ref1" />. |
| − | FEZF1-AS1 could act as an "oncogene" for gastric cancer partly through suppressing P21 expression; FEZF1-AS1 may be served as a candidate prognostic biomarker and target for new therapies of gastric cancer patients <ref name="ref2" />. FEZF1-AS1 is overexpressed in gastric cancer, and upregulated FEZF1-AS1 expression is correlated with larger tumor size and higher clinical stage; additional higher expression of FEZF1-AS1 predicted poor prognosis <ref name="ref2" />. FEZF1-AS1 could epigenetically repress the expression of P21 via binding with LSD1 (a demethylase) <ref name="ref2" />. | + | *FEZF1-AS1 could act as an "oncogene" for gastric cancer partly through suppressing P21 expression; FEZF1-AS1 may be served as a candidate prognostic biomarker and target for new therapies of gastric cancer patients <ref name="ref2" />. FEZF1-AS1 is overexpressed in gastric cancer, and upregulated FEZF1-AS1 expression is correlated with larger tumor size and higher clinical stage; additional higher expression of FEZF1-AS1 predicted poor prognosis <ref name="ref2" />. FEZF1-AS1 could epigenetically repress the expression of P21 via binding with LSD1 (a demethylase) <ref name="ref2" />. |
| + | |||
| + | [[File:FEZF1-AS1-fun.png|right|thumb|400px|An illustrative figure detailing the relationship among FEZF1-AS1, miR-610 and Akt3.<ref name="ref3" />.]] | ||
| + | *FEZF1-AS1 inhibition reduced myeloma (MM) cells proliferation, arrested cell cycle in G0/G1 phase and induced cell apoptosis. Furthermore, FEZF1-AS1 promoted MM cells progression by regulating miR-610/Akt3 axis<ref name="ref3" />. | ||
===Expression=== | ===Expression=== | ||
FEZF1-AS1 is overexpressed in gastric cancer, and upregulated FEZF1-AS1 expression is correlated with larger tumor size and higher clinical stage; additional higher expression of FEZF1-AS1 predicted poor prognosis <ref name="ref2" />. | FEZF1-AS1 is overexpressed in gastric cancer, and upregulated FEZF1-AS1 expression is correlated with larger tumor size and higher clinical stage; additional higher expression of FEZF1-AS1 predicted poor prognosis <ref name="ref2" />. | ||
| + | |||
| + | Expression of FEZF1-AS1 was upregulated in myeloma (MM) samples and cell lines<ref name="ref3" />. | ||
===Disease=== | ===Disease=== | ||
*Colorectal carcinoma<ref name="ref1" /> | *Colorectal carcinoma<ref name="ref1" /> | ||
*Gastric cancer<ref name="ref2" /> | *Gastric cancer<ref name="ref2" /> | ||
| + | *Myeloma (MM) | ||
===Sequence=== | ===Sequence=== | ||
| Line 83: | Line 97: | ||
<ref name="ref2"> | <ref name="ref2"> | ||
Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C, Ji G. | Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C, Ji G. | ||
| − | LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation | + | LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol Cancer. 2017 Feb 16;16(1):39. |
| − | through LSD1-Mediated H3K4me2 demethylation. Mol Cancer. 2017 Feb 16;16(1):39. | + | </ref> |
| + | <ref name="ref3"> | ||
| + | Li QY, Chen L, Hu N, Zhao H. Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610/Akt3 axis. Biomed Pharmacother. 2018 Jul;103:1727-1732. | ||
</ref> | </ref> | ||
</references> | </references> | ||
Latest revision as of 01:31, 14 August 2019
Contents
Annotated Information
Name
Approved symbol: FEZF1-AS1:FEZF1 antisense RNA 1[1]
HGNC ID: HGNC:41001
Ensembl ID: ENSG00000230316
RefSeq ID: NR_036484
LncBook transcript ID: HSALNT0288975
Characteristics
FEZF1-AS1 is a ~2.6-kb RNA transcribed from the plus strand of chromosome 7 [1][2]. FEZF1-AS1 is transcribed from the opposite strand of FEZF1 protein (7q31.32), and there are 611 nucleotides of full complementarity between the frst FEZF1-AS1 exon and FEZF1 exons 1 [1].
Function
FEZF1-AS1 regulates GC cell proliferation[2].
- Dysregulation of FEZF1-AS1 participates in colorectal tumorigenesis and progression, which might be achieved, at least in part, through FEZF1 induction [1].
- FEZF1-AS1 could act as an "oncogene" for gastric cancer partly through suppressing P21 expression; FEZF1-AS1 may be served as a candidate prognostic biomarker and target for new therapies of gastric cancer patients [2]. FEZF1-AS1 is overexpressed in gastric cancer, and upregulated FEZF1-AS1 expression is correlated with larger tumor size and higher clinical stage; additional higher expression of FEZF1-AS1 predicted poor prognosis [2]. FEZF1-AS1 could epigenetically repress the expression of P21 via binding with LSD1 (a demethylase) [2].
An illustrative figure detailing the relationship among FEZF1-AS1, miR-610 and Akt3.[3].
- FEZF1-AS1 inhibition reduced myeloma (MM) cells proliferation, arrested cell cycle in G0/G1 phase and induced cell apoptosis. Furthermore, FEZF1-AS1 promoted MM cells progression by regulating miR-610/Akt3 axis[3].
Expression
FEZF1-AS1 is overexpressed in gastric cancer, and upregulated FEZF1-AS1 expression is correlated with larger tumor size and higher clinical stage; additional higher expression of FEZF1-AS1 predicted poor prognosis [2].
Expression of FEZF1-AS1 was upregulated in myeloma (MM) samples and cell lines[3].
Disease
Sequence
>NR_036484.1 Homo sapiens FEZF1 antisense RNA 1 (FEZF1-AS1), long non-coding RNA
000001 GAAAACTTTG GGCTTGGCAT TAGGAGAGCC TCGGCTGAAA TCCGAGGTTT TGAACGCGAT TTTTTCCGAC AGAAGCTGGG 000080
000081 CGCTTTCTTT CATGTAATGC TGCAGCTGAG CCTGGGACAG GTCTTTGAAA GCTACTCCAG AAGGGTATTT CTCCACCGCC 000160
000161 GGGACCACCA GTTTATTCCT TTCGGCTAAA TACGTTTTTG GCTGCGGGTG CAAAGGGGAA CTGAGGAAGT AGGAGGCCAC 000240
000241 CGGGTGGATG TTCACGCCGG CTGCCGGGTG GCATGGGCCG TCACCTCGGT TCAGGTAGCA CAAGGCGCCC ATGGCGTGGA 000320
000321 ATGAAGAGTG GTTGACCACA CGCGGCCTTA CCAGCTTGTA CTGCTGCAGC GGCAGCGCGT CGCGGGCCAG GTCGCCCTTG 000400
000401 AGACTCAGTG CGCAGTTGAG CAGGTCGCTG CAGCTGAATG CGGGAGCCGA GGGCACCGCC GCGGGCGCCG CCGGGGCCTC 000480
000481 CAGACTGGCC TTCCGCGGCT CGGAGCCCGT CACTCCTGCC TTGGGGCTCG TGTCGTAGGC CACAGGCACG AAGGGGATCA 000560
000561 TGCAGGGGAT CGACGAGTTG AGATGCAGAG AGTGCTTGGG TTCCCCCTTG GCATCACCAG CCGAACCTGC CTGCCCAGCC 000640
000641 CAATGGACTC CTGCCAGCCC ATCGCAGAGT TCTTGGCGCA CCAATGACTC GGGGACAATC ACTACTTATT TCTATCAATA 000720
000721 GAAAGTGTTG TGTCAATAAC GCAGCCAAGA TCTCGCCAAT CGTTAACTTC CAAGAGGAGA AGGGCTCGGG GTTGCCCGCT 000800
000801 CCCGGAATCC CGGAGTCTCC GCGGCCCGAA CCGAGTCTGG ACCATTTAGA AGACGCCGGC AGGTAACTGG CCTCCCCAAA 000880
000881 CGCCCCGAAA ATTAAAAGCC TTAGGAGGCT TGTTCTGTGT TTGTGGTTTT GTAAAGGCAA TGCCCGCGGC AATAGGCCTG 000960
000961 GGAAAGTCGC ACTTTCATCC ACAAAGTTGA GGAGTTGCAA GGAATAATTG GGTGTCACAC CACAAGCAAC CTTGACTCGA 001040
001041 TCGGACCCCA CCCAGGATAC ACACAGACGC GCGCGCGCGC ACGCTTCCGA GTTTCCATTG AGAGTCTGGA AAGAGCATTT 001120
001121 CTTTCTTAAG TACCTGCGCT CAGCTAGAGC TCTCCCGGAG CATTTTAAAT ACTGAATGCC GAGCGGAGAA GGGAAACAGA 001200
001201 GTGTATTAAT CCCCACTCCG GTTGCCGGTG TCTGCAAGCC TCCTCTAAGC AGCGCAGGCG GCAGCCTGGA TGTCTGTGCG 001280
001281 CATCAAGGAG ACTTGCCGGC GCCAGAGTTG TGTCCACAGG TGCACTTGTG CCTCCCAAAG AGCGCGCGTA GAGACCATTT 001360
001361 CCCCTGCAAC GCCCCCCAGC CGAACACCCG CCGGGTGTGG CACCTCGGCC GAAACTCCTG GGGCGGCGCG GTGGAGCGTG 001440
001441 TGGAGGTTTC CGGGAAGACG CCTACGGCTG CGGCTCCGAC TGTGCGGGCT CCCGCCGCCC AGGCAAGAGC GTCCAGGAGC 001520
001521 GCGCTGGAAG CTGCGGCGCG CACCTTCCCC GGCGCAGTCT CTTGCCAGCC GGCGATCACG CAGAGCTGAA CCCCGCAGCT 001600
001601 AGGCGCGCAG GAAGGGCTGC ACAGAGTTTG AAGACACGGC AGCTGTAAGC TGGCGTGAGG AGGCCAAAGG AGCGCGCAGA 001680
001681 GCTGCAAGCA AAGGGCGGTG GGGCCTGGAC CCTGAAGTGA GTGGCCGACC GCAGCAGCTC AAGGTGCCAT CTGCCTGGCA 001760
001761 AGCTACCCGG GTCCCTCCGC CCCACTCTAA CTTTCCGCGA AAATCAGTTC CGCCTCTGCC CCAAGAGCCA AGAGGGGTGG 001840
001841 AAAGGAAGAG AGCTTGGGCT GGGAACGCGC CTGATGTCTA ACAGAAAGGC AGTGGCAGCT GGCGAAAAAT CCCCCTCCTG 001920
001921 CTGCACTCCT CCGCCACCGG GCTAGGTTGA AAGGAAAAAG CCAAGAAGCG CGAAGCAGCC CGGCTCTGGA AGGCTTTGGA 002000
002001 GAGTCCAGCT GACTTGTACA CAATTCGCGG CCTCTGGAGC CTTACCTGCC TTCTTGACTG AATGCCACCA GTTCGTTTTA 002080
002081 CGCTTGTGGC TTTTTGTTGA AGTCCCTATC ATAAGCAAAT GCAGTTTCTG GCTATGGTTA CTGCAATTCG AAATAAAAGG 002160
002161 CCTGTGAGGT GTGTCCCTCC AGACTGAGAG GCTATGACTC AGGGTTGGAC TTTATGGAAA AAAAGAAGTT TATAAAACAA 002240
002241 GTAACCCAGT TTCTCCAACC TTTACTGTGG AGCAACAGCG TCAAGCAACA AAACCCAGCA AAGTTTTGCT TGTCACTTAC 002320
002321 AAGGGTGTTA CTGAAATCTG GAAGGCGAAC AATTAGAAGA TAGCCCAAAC ATGCTCTATT GCTCTACACT GAAATACTTG 002400
002401 CCTCCAATAA TAGAAAAAAC CTGTTTTCGT GCAATTGATT GATTAGCGTT CTGCAGCAGT CCCTGGACAA TTTTAAAGAC 002480
002481 ATTTTGTGTT TGTGGCCAAA ATTAGAAACA AGCAGACACA CACACAAAAC AACCATATTC AAGACACGGT TCGACTGTTT 002560
002561 CCTTGACACT ACCCACGAAG TTTAAAGCAT TTTTTATGTT ATTTTCAAAC TTTCTTAAGT GATCCCATGA AATAAAAGTC 002640
002641 GATAATAGAA ATT
000081 CGCTTTCTTT CATGTAATGC TGCAGCTGAG CCTGGGACAG GTCTTTGAAA GCTACTCCAG AAGGGTATTT CTCCACCGCC 000160
000161 GGGACCACCA GTTTATTCCT TTCGGCTAAA TACGTTTTTG GCTGCGGGTG CAAAGGGGAA CTGAGGAAGT AGGAGGCCAC 000240
000241 CGGGTGGATG TTCACGCCGG CTGCCGGGTG GCATGGGCCG TCACCTCGGT TCAGGTAGCA CAAGGCGCCC ATGGCGTGGA 000320
000321 ATGAAGAGTG GTTGACCACA CGCGGCCTTA CCAGCTTGTA CTGCTGCAGC GGCAGCGCGT CGCGGGCCAG GTCGCCCTTG 000400
000401 AGACTCAGTG CGCAGTTGAG CAGGTCGCTG CAGCTGAATG CGGGAGCCGA GGGCACCGCC GCGGGCGCCG CCGGGGCCTC 000480
000481 CAGACTGGCC TTCCGCGGCT CGGAGCCCGT CACTCCTGCC TTGGGGCTCG TGTCGTAGGC CACAGGCACG AAGGGGATCA 000560
000561 TGCAGGGGAT CGACGAGTTG AGATGCAGAG AGTGCTTGGG TTCCCCCTTG GCATCACCAG CCGAACCTGC CTGCCCAGCC 000640
000641 CAATGGACTC CTGCCAGCCC ATCGCAGAGT TCTTGGCGCA CCAATGACTC GGGGACAATC ACTACTTATT TCTATCAATA 000720
000721 GAAAGTGTTG TGTCAATAAC GCAGCCAAGA TCTCGCCAAT CGTTAACTTC CAAGAGGAGA AGGGCTCGGG GTTGCCCGCT 000800
000801 CCCGGAATCC CGGAGTCTCC GCGGCCCGAA CCGAGTCTGG ACCATTTAGA AGACGCCGGC AGGTAACTGG CCTCCCCAAA 000880
000881 CGCCCCGAAA ATTAAAAGCC TTAGGAGGCT TGTTCTGTGT TTGTGGTTTT GTAAAGGCAA TGCCCGCGGC AATAGGCCTG 000960
000961 GGAAAGTCGC ACTTTCATCC ACAAAGTTGA GGAGTTGCAA GGAATAATTG GGTGTCACAC CACAAGCAAC CTTGACTCGA 001040
001041 TCGGACCCCA CCCAGGATAC ACACAGACGC GCGCGCGCGC ACGCTTCCGA GTTTCCATTG AGAGTCTGGA AAGAGCATTT 001120
001121 CTTTCTTAAG TACCTGCGCT CAGCTAGAGC TCTCCCGGAG CATTTTAAAT ACTGAATGCC GAGCGGAGAA GGGAAACAGA 001200
001201 GTGTATTAAT CCCCACTCCG GTTGCCGGTG TCTGCAAGCC TCCTCTAAGC AGCGCAGGCG GCAGCCTGGA TGTCTGTGCG 001280
001281 CATCAAGGAG ACTTGCCGGC GCCAGAGTTG TGTCCACAGG TGCACTTGTG CCTCCCAAAG AGCGCGCGTA GAGACCATTT 001360
001361 CCCCTGCAAC GCCCCCCAGC CGAACACCCG CCGGGTGTGG CACCTCGGCC GAAACTCCTG GGGCGGCGCG GTGGAGCGTG 001440
001441 TGGAGGTTTC CGGGAAGACG CCTACGGCTG CGGCTCCGAC TGTGCGGGCT CCCGCCGCCC AGGCAAGAGC GTCCAGGAGC 001520
001521 GCGCTGGAAG CTGCGGCGCG CACCTTCCCC GGCGCAGTCT CTTGCCAGCC GGCGATCACG CAGAGCTGAA CCCCGCAGCT 001600
001601 AGGCGCGCAG GAAGGGCTGC ACAGAGTTTG AAGACACGGC AGCTGTAAGC TGGCGTGAGG AGGCCAAAGG AGCGCGCAGA 001680
001681 GCTGCAAGCA AAGGGCGGTG GGGCCTGGAC CCTGAAGTGA GTGGCCGACC GCAGCAGCTC AAGGTGCCAT CTGCCTGGCA 001760
001761 AGCTACCCGG GTCCCTCCGC CCCACTCTAA CTTTCCGCGA AAATCAGTTC CGCCTCTGCC CCAAGAGCCA AGAGGGGTGG 001840
001841 AAAGGAAGAG AGCTTGGGCT GGGAACGCGC CTGATGTCTA ACAGAAAGGC AGTGGCAGCT GGCGAAAAAT CCCCCTCCTG 001920
001921 CTGCACTCCT CCGCCACCGG GCTAGGTTGA AAGGAAAAAG CCAAGAAGCG CGAAGCAGCC CGGCTCTGGA AGGCTTTGGA 002000
002001 GAGTCCAGCT GACTTGTACA CAATTCGCGG CCTCTGGAGC CTTACCTGCC TTCTTGACTG AATGCCACCA GTTCGTTTTA 002080
002081 CGCTTGTGGC TTTTTGTTGA AGTCCCTATC ATAAGCAAAT GCAGTTTCTG GCTATGGTTA CTGCAATTCG AAATAAAAGG 002160
002161 CCTGTGAGGT GTGTCCCTCC AGACTGAGAG GCTATGACTC AGGGTTGGAC TTTATGGAAA AAAAGAAGTT TATAAAACAA 002240
002241 GTAACCCAGT TTCTCCAACC TTTACTGTGG AGCAACAGCG TCAAGCAACA AAACCCAGCA AAGTTTTGCT TGTCACTTAC 002320
002321 AAGGGTGTTA CTGAAATCTG GAAGGCGAAC AATTAGAAGA TAGCCCAAAC ATGCTCTATT GCTCTACACT GAAATACTTG 002400
002401 CCTCCAATAA TAGAAAAAAC CTGTTTTCGT GCAATTGATT GATTAGCGTT CTGCAGCAGT CCCTGGACAA TTTTAAAGAC 002480
002481 ATTTTGTGTT TGTGGCCAAA ATTAGAAACA AGCAGACACA CACACAAAAC AACCATATTC AAGACACGGT TCGACTGTTT 002560
002561 CCTTGACACT ACCCACGAAG TTTAAAGCAT TTTTTATGTT ATTTTCAAAC TTTCTTAAGT GATCCCATGA AATAAAAGTC 002640
002641 GATAATAGAA ATT
Labs working on this lncRNA
- Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
- Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.[1]
- Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, People's Republic of China.
- Department of Laboratory, Affiliated Chest Hospital of southeast University, Nanjing, Jiangsu, People's Republic of China.
- Department of surgery, Affiliated the second hospital of Bengbu Medical College, Lianyungang, jiangsu, People's Republic of China.
- Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
- Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China. lyw0171@outlook.com.
- Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, People's Republic of China. wangcailian65@hotmail.com.
- Department of Gastroenterology Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China. nyefygz@163.com.[2]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Chen N, Guo D, Xu Q, Yang M, Wang D, Peng M, Ding Y, Wang S, Zhou J. Long non-coding RNA FEZF1-AS1 facilitates cell proliferation and migration in colorectal carcinoma. Oncotarget. 2016 Mar 8;7(10):11271-83.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C, Ji G. LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol Cancer. 2017 Feb 16;16(1):39.
- ↑ 3.0 3.1 3.2 Li QY, Chen L, Hu N, Zhao H. Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610/Akt3 axis. Biomed Pharmacother. 2018 Jul;103:1727-1732.
